Formulation and Evaluation of Chronomodulated Pulsatile Drug Delivery System of Salbutamol Sulphate

Author(s)

Anusha, V., Shanthi, G., Khobragade, D. S.

Author's Affiliation

Abstract

Chronotherapy denotes the therapy in which the release of the drug in the body is allowed to match with the circadian rhythm of the disease, such that the required action of the drug is shown with minimal side effects. The main interesting fact of chronotherapy is its ability to deliver the drug in required concentrations during the time of its greatest need such that synchronizing circadian rhythm of diseases or symptoms. Pulsatile drug delivery system for Salbutamol sulphate was formulated initially as core tablets followed by formulation of pulsatile tablets using press-coated technology. Core tablets were formulated using various concentrations of superdisintegrant (Sodium starch glycolate, cross povidone) and diluents (MCC & Dicalcium phosphate). The core tablets were then compressed into pulsatile tablets using combinations of HPMC K 100M and Eudragit L 100, Eudragit S 100 in various concentrations. Core tablets were evaluated and based on the dissolution studies trial T3was optimized as it shows lower disintegration time and faster drug release. Then the pulsatile tablets were evaluated for various tests and drug release studies were conducted for 2 hours in 0.1N HCl followed by pH 6.8 buffer and the trial S6 was optimized which showed satisfactory greater lag time of about 6 hours with satisfactory drug release which contains a combination of HPMC K15M (20mg), Eudragit L 100 (50mg), Eudragit S100 (60mg). Pulsatile tablets were formulated utilizing press coated technology and the combination of polymers provided required lag time with satisfactory dissolution profile.

Keywords

Pulsatile, Lag Time, Salbutamol Sulphate, Drug Release

Cite This Article

Anusha, V., Shanthi, G., & Khobragade, D. S. (2015). Formulation and Evaluation of Chronomodulated Pulsatile Drug Delivery System of Salbutamol Sulphate, International Journal for Pharmaceutical Research Scholars (IJPRS), 4(4), 157-166.